Skip to main content
. 2019 Apr 30;11(5):e9960. doi: 10.15252/emmm.201809960

Figure EV2. cMet, FAK, and Src phosphorylation regulation in epithelial and mesenchymal non–small‐cell lung cancer cell lines following Plk1 inhibition.

Figure EV2

  • A
    Box plots show protein expression of p‐cMet (Y1234/35), pFAK (Y397), and pSrc (Y416) measured using reverse phase protein array after treatment with volasertib in non–small‐cell lung cancer cell lines. Experiments were performed in triplicate. The median is marked by a horizontal line, the colored boxes are the upper and lower quartiles, and error bars represent standard deviation. FC, fold change.
  • B
    Three epithelial (H1975, HCC4006, and HCC366) and two mesenchymal (Calu6 and H1792) NSCLC cell lines were incubated with 50 nM volasertib for 24 h, lysed, and subjected to reverse phase protein array analysis. Experiments were done in triplicate.
  • C
    Seventy proteins were differentially regulated between epithelial and mesenchymal NSCLC cell lines after treatment with volasertib, including those involved in the cMet/FAK/Src signaling axis proteins (blue text) and the PI3K/Akt signaling axis (orange text). FDR, false discovery rate.